BOSTON (MarketWatch) -- Drug stocks slipped Monday morning as shares of Amgen Inc. eased after clinical data that showed its leading anemia drug Aranesp was ineffective in helping control tumor growth in certain breast cancer patients.
BOSTON (MarketWatch) -- Drug stocks slipped Monday morning as shares of Amgen Inc. eased after clinical data that showed its leading anemia drug Aranesp was ineffective in helping control tumor growth in certain breast cancer patients.
